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Pseudoangiomatous stromal hyperplasia (PASH) is a benign entity of the breast and typically found
incidentally. It warrants thorough investigation in order to exclude more sinister pathology
masquerading as this form of benign breast disease and can often be managed expectantly without the
need for surgical intervention. We provide a brief review of the literature on PASH, discussing its clin-
icopathological features and management.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.Pseudoangiomatous stromal hyperplasia (PASH) was ﬁrst
described by Vuitch, Erlandson and Rosen in 1986.1 In their report,
9 women with palpable, circumscribed, non-haemorrhagic breast
masses were studied. On histological examination, they found the
masses to be composed of mammary stromal proliferations with
complex anastomosing channels lined with slender spindle cells
simulating vascular channels. The term “pseudoangiomatous”
described this histological appearance which resembles, without
actually constituting, an angiomatous proliferation and indeed they
emphasised the importance of distinguishing this benign lesion
from other vascular tumours such as low-grade angiosarcoma.
Less than 200 cases of PASH have been described in the English
literature with the largest series including 40 cases.2 PASH is an
incidental histological ﬁnding in the vast majority of cases and was
reported as being present in 23% of 200 consecutive breast speci-
mens resected for various benign and malignant conditions3 and in
24e47% of men with gynaecomastia.4 PASH may also present as
a mass or nodule and is typically single, circumscribed, rubbery and
mobile, typically in pre-menopausal women, and consequently is
most frequentlymisdiagnosed as a ﬁbroadenoma. The lesion is pale,
ﬁbrous and has a homogenous cut surface. Masses vary in size with
reporteddiameters ranging between 1 and 12 cm.5 The reported age
range of patients is 14e67 years although the vast majority of PASH
patients present in their late thirties and forties.6 A malignant
counterpart for PASH has not been described in the literature withciates Ltd. Published by Elsevier Ltthe exception of “two instances of tumour forming PASH in teenage
girls characterised by marked cytological atypia, multinucleated
cells and mitotic activity regarded as myoﬁbroblastic sarcoma” in
the book Rosen’s Breast Pathology.7
1. Aetiology
PASH is associated with several benign entities including
proliferative and non-proliferative ﬁbrocystic changes, ﬁbroade-
nomas, gynaecomastia, normal breast tissue and sclerosing lobular
hyperplasias. The aetiology and pathogenesis remain unknown.
Hormonal factors are thought to play a role in the aetiology of
PASH. Ibrahim et al.3 found that the average age of patients with
PASH was 40 years. Among 65 patients older than 50 years, only 5
had PASH. Although the hormonal status of the patients was not
given, the rarity of PASH in patients older than 50 years concurs
with the conclusions of Vuitch et al.1 and suggests a hormonal basis
for PASH. Two of the patients included in the study of Ibrahim et al.3
were male and each was considered to have both PASH and
gynaecomastia. The histological similarity of the stromal changes in
PASH and gynaecomastia represents a response in the male breast
to hormonal stimulation.
Further evidence for a hormonal aetiology comes from
Anderson et al.8 who studied 5 cases of PASH. All of the patients
were pre- or peri-menopausal. Patchy, intense stromal cell
progesterone-receptor (PR) positivity was present in PASH in all
cases. Faint stromal nuclear reactivity for oestrogen-receptors (ER)
was observed in one case. The nuclei of control stromal cells outside
PASH failed to stain for either receptor. Powell et al.2 found that oned. All rights reserved.
Fig. 1. Hematoxylineeosin staining of a PASH specimen showing a complex pattern of
anastomosing slit-like spaces in a dense collagenous stroma. These spaces are lined
with myoﬁbroblasts rather than endothelial cells and do not contain red blood cells.
Fig. 2. Ultrasound image showing a heterogeneous, hypoechoic, circumscribed mass
containing anechoic areas.
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rienced temporary control of extensive PASH. Furthermore, they
also observed in another patient that a contralateral lesion,
incompletely excised, ﬂuctuated with menses thus indicating
a capacity for hormone-related responsiveness.
Traditionally, the mammary stroma is divided into an intra-
lobular component which is hormonally sensitive and an inter-
lobular component that is relatively unresponsive to hormones.
The lobular stroma and epithelium change during the menstrual
cycle. The lobulocentric pattern seen in mass lesions and in inci-
dental PASH is similar to lobular stromal changes seen during the
luteal phase of the menstrual cycle suggesting that PASH could be
the result of expansion of the intralobular stroma. The ﬁnding in
PASH of distorted acini, the absence of ducts and effacement of the
usual intralobulareextralobular distinction supports the concept of
lobular stromal expansion.
On gross pathological analysis, tumoural PASH is usually a well-
circumscribed ﬁbrous mass which can be white, grey or tan in
colour. Occasionally, cysts may be found within the lesion. Necrosis
and haemorrhage are rare except for lesions that have been sub-
jected to ﬁne-needle aspiration cytology (FNAC) or core-needle
biopsy (CNB).
Microscopically, PASH consists of a network of slit-like spaces
lined by myoﬁbroblasts that resemble vascular spaces. The inter-
vening stroma consists of collagen. Occasionally, PASH lesions have
been confused and indeed misdiagnosed as low-grade angio-
sarcomawhich is characterised by anastomosing vascular channels
with invasion into the breast parenchyma, papillary endothelial
growth and hyperchromatic endothelial cells. In contrast, the
channels found in PASH are not true vascular spaces but thought to
be due to disruption and separation of stromal collagen ﬁbres. In
cases proving to be difﬁcult diagnostically, immunohistochemistry
is of great use. PASH has an immunophenotypic proﬁle character-
istic of myoﬁbroblasts. The spindle cells are positive for Vimentin,
CD34, BCL2, CD99 and a-smoothmuscle actin but negative for CD31
and factor VIII (an endothelium-speciﬁc marker). In addition, the
cells are hormonally sensitive and frequently express PR and less
frequently ER (as previously mentioned). PASH has also occurred as
an incidental ﬁnding in cases of invasive adenocarcinomas,
however, a ﬁnding of PASH does not require an extensive search for
associated malignancy. PASH is not considered premalignant;
invasive or in situ carcinoma has not been reported within a PASH
nodule. It is also neither considered a risk factor for cancer nor is it
associated with synchronous cancer.
2. Investigation
The radiological ﬁndings in PASH are non-speciﬁc and may
resemble those of ﬁbroadenomas.9 Mammographically, PASH, when
seen, appears as an ovalmasswithout associatedmicrocalciﬁcations.
Further assessment with ultrasonography typically reveals an oval,
irregular, hypoechoic, or mixed echogenic mass without posterior
acoustic enhancement or shadowing. However, ultrasound charac-
teristics of PASHexhibitmarkedvariability.Mercadoet al.10 evaluated
the sonographic features of 13 patients with a histological diagnosis
of PASH and observed that 11 of the 13 lesions were hypoechoic. All
lesionswere oval and demonstrated no posterior acoustic shadowing
(Figs. 1 and 2).
The use of MRI in assessing PASH has not yet been adequately
studied. It is our opinion that current imaging modalities are not
speciﬁc enough to make a ﬁrm diagnosis of PASH without tissue
diagnosis.
Fine-needle aspiration cytology of PASH often produces acel-
lular specimens.When tissue is present, the cytological ﬁndings are
similar to those of ﬁbroadenomas, although the smears are muchless cellular.11 The lower cellularity in PASH aspirates may be
related to the associated stromal hyalinisation. However, sampling
techniques also play a signiﬁcant role in determining overall
cellularity of a ﬁne-needle aspirate. The ductal epithelial compo-
nent often assumes a nondescript club shape and sometimes
a staghorn conﬁguration. Epithelial cell clusters show variable sizes
withmedium to small groups, and stromal elements areminimal or
absent. The background cells are composed of round to oval naked
nuclei and spindle shapes. Occasionally, epithelial clusters show
cellular dissociation and slight atypia.
Core-needle biopsy is far more accurate than ﬁne-needle aspi-
ration cytology (FNAC) for diagnosing PASH. Wai-Kuen Ng et al.12
concluded that FNAC ﬁndings in PASH are non-speciﬁc and that
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provide a deﬁnitive pre-operative diagnosis. The presence of
spindle cells on CNB or FNAC is not unique to PASH. Phylloides
tumours, desmoid tumours and other tumours may contain spindle
cells similar to those seen in PASH. As previously discussed, PASH
may also mimic low-grade angiosarcoma histologically, leading to
unnecessary radical surgery if not recognised. In our review of the
English literature, there are case reports but no studies evaluating
the accuracy of CNB as a method of diagnosing PASH.
3. Management
Many authors recommend wide local excision as the treatment
of choice for PASH due to its uncertain natural history.4 Generally
speaking, excision should be considered for symptomatic patients,
enlarging lesions, BI-RADS 4 or 5 lesions and patients with
discordance following triple assessment. A recently published
study showed that non-surgical management can be considered in
patients who refuse a surgical procedure and options may be
acceptable, especially when the lesion is small and triple assess-
ment has been performed to exclude malignancy although no
studies have yet evaluated the long-term clinical outcome of such
cases that are managed by surveillance.13 Some reports document
an impressive response to tamoxifen in a patient presenting with
breast enlargement, pain and breast masses, however long-term
use may not be ideal, considering the potential side effects.14
The recurrence rates of PASH after excision are reported to range
from 15 to 22%15,16 although longer follow-up studies are needed to
evaluate the recurrence rate. The reason for recurrence could be
attributed to growth of a residual mass after incomplete excision,
the presence of multiple lesions that were not all excised, or de novo
growth of PASH. Some studies have reported cases where PASH has
regressed spontaneously.2
4. Conclusion
PASH is a rare benign entity that is regarded as myoﬁbroblastic
proliferation of the breast and local excision is curative in the
majority of cases. Although recurrence may occur the overall rate is
low. As is evident fromour discussion, the FNACﬁndings of PASH are
very non-speciﬁc. Therefore, the role of FNAC in PASH is merely to
conﬁrm benignancy. Rarely, because of the epithelial atypia and
discohesiveness of the cells the suspicion of malignancy may arise,
whilst the stromal hypercellularity and atypiamaycause amistakendiagnosis of phylloides tumour. In such rare instances, the
mammographic and ultrasonographic ﬁndingsmayaid in excluding
carcinoma. However, if the imaging ﬁndings are equivocal, a histo-
logical examination is mandatory for a deﬁnitive diagnosis.Conﬂict of interest
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